Anti-human CD40 monoclonal antibody therapy is potent without FcR crosslinking

Antibody agonists targeting tumor necrosis factor (TNF) superfamily receptors, including CD40, are being tested therapeutically as anticancer agents. Studies in mice have shown that anti-CD40 monoclonal antibody (mAb) requires Fc-receptor (FcR) engagement to activate antitumor immunity. In contrast,...

Full description

Saved in:
Bibliographic Details
Main Authors: Richman, Lee P, Vonderheide, Robert H
Format: Artigo
Language:Inglês
Published: Landes Bioscience 2014
Subjects:
Author's View
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC4091558/
https://ncbi.nlm.nih.gov/pubmed/25097801
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4161/onci.28610
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items